Incretin & metabolic research compounds
Survodutide
Also known as BI 456906
A dual glucagon-receptor / GLP-1-receptor agonist being developed for obesity and metabolic liver disease (MASH).
In 60 seconds
Phase 2 in obesity and MASH (2024); phase 3 obesity results reported in 2026. Trials report gastrointestinal events as the main tolerability issue, with dose-escalation studied to manage them.
- Describes the discovery and preclinical pharmacology of survodutide as an oxyntomodulin-like dual agonist.
- A phase 2 dose-finding trial measured survodutide’s effect on body weight and its tolerability.
- A phase 2 trial measured histological improvement in MASH with survodutide.
Mechanism
Modelled on oxyntomodulin, survodutide activates both the GLP-1 receptor (appetite, insulin) and the glucagon receptor (energy expenditure, hepatic fat metabolism) — the rationale for its liver-disease programme.
Research status
Phase 2 in obesity and MASH (2024); phase 3 obesity results reported in 2026. Not yet approved.
Key studies
Describes the discovery and preclinical pharmacology of survodutide as an oxyntomodulin-like dual agonist.
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy — Mol Metab, 2022 · PMID 36356832
A phase 2 dose-finding trial measured survodutide’s effect on body weight and its tolerability.
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial — Lancet Diabetes Endocrinol, 2024 · PMID 38330987
A phase 2 trial measured histological improvement in MASH with survodutide.
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis — N Engl J Med, 2024 · PMID 38847460
A phase 3 trial of once-weekly survodutide in adults with obesity.
Survodutide Once Weekly for the Treatment of Adults with Obesity — N Engl J Med, 2026 · PMID 42253238
Safety signals in the literature
Trials report gastrointestinal events as the main tolerability issue, with dose-escalation studied to manage them.
Legal status (South Africa)
Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
Related compounds we stock
Not stocked yet — get notified
Tell us you want Survodutide and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add Survodutide
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is Survodutide?
A dual glucagon-receptor / GLP-1-receptor agonist being developed for obesity and metabolic liver disease (MASH). Modelled on oxyntomodulin, survodutide activates both the GLP-1 receptor (appetite, insulin) and the glucagon receptor (energy expenditure, hepatic fat metabolism) — the rationale for its liver-disease programme.
What is the research status of Survodutide?
Phase 2 in obesity and MASH (2024); phase 3 obesity results reported in 2026. Not yet approved.
What safety signals are reported for Survodutide?
Trials report gastrointestinal events as the main tolerability issue, with dose-escalation studied to manage them.
Does Living Water Labs stock Survodutide?
Not at present. Survodutide is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
More in Incretin & metabolic
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
